Physician profile
James K Beebe
NPI 1881691442
$3,135.12
in general payments reported to CMS, 2019-2025
26 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $554 · 2021: $106 · 2022: $222 · 2023: $255 · 2024: $309 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $642.86 | 2019-2024 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $456.67 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $325.04 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $237.86 | 2019-2023 | |
| Glaxosmithkline, LLC. | $226.37 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $180.02 | 2019-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $165.82 | 2021-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.72 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $126.19 | 2019-2020 | |
| Astellas Pharma US INC | $79.28 | 2019-2024 | Veozah |
| Allergan, INC. | $72.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.48 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $56.93 | 2019-2020 | |
| Shire North American Group INC | $46.16 | 2019 | |
| Merck Sharp & Dohme LLC | $42.44 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.20 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $38.29 | 2024-2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $37.99 | 2019-2020 | |
| Amarin Pharma, INC. | $32.55 | 2019-2020 | |
| Daiichi Sankyo INC. | $24.46 | 2019-2020 | |
| Esperion Therapeutics, INC. | $22.98 | 2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $21.59 | 2019 | |
| Dynavax Technologies Corporation | $17.00 | 2023 | Heplisav-B |
| Livanova USA, INC. | $15.83 | 2019 | |
| Genentech USA, INC. | $13.80 | 2019 | |
| Sanofi Pasteur INC. | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Beebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.